vimarsana.com

Page 5 - சமூகம் ஆஃப் பெண்ணோயியல் புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results News provided by Share this article Share this article CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/  Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap Highlights: Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients

Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women s Cancer

Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women s Cancer Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer News provided by Share this article Share this article WOODCLIFF LAKE, N.J., March 10, 2021 /PRNewswire/  Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women s Cancer, March 19-25 (#SGOMtg). These investigational data include the first presentation of efficacy and safety results from the KEYNOTE-775/Study 309 study, a multi-center, randomized, open-label, Phase 3 trial (NCT03517449) evaluating KEYTRUDA in combination with LENVIMA in certa

AAGL, in Partnership with Ten Leading Women s Health Care Groups, Issue a Joint Statement Regarding the COVID-19 Vaccine

AAGL, in Partnership with Ten Leading Women’s Health Care Groups, Issue a Joint Statement Regarding the COVID-19 Vaccine Share Article The American Association of Gynecologic Laparoscopists (AAGL) announces their endorsement of the U.S. Food and Drug Administration (FDA) authorized Pfizer/BioNTech COVID-19 vaccine, for eligible populations, through a joint public health statement with ten respected women’s health medical societies. AAGL is an international professional medical association of laparoscopic surgeons and the global leader in minimally invasive gynecologic surgery. Leading Women’s Health Care Groups, Issue a Joint Statement Regarding the COVID-19 Vaccine CYPRESS, Calif. (PRWEB) December 17, 2020 The American Association of Gynecologic Laparoscopists (AAGL), the American College of Obstetricians and Gynecologists (ACOG), the American Society for Reproductive Medicine (ASRM), American Urogynecolo

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.